U.S. Pauses Allocation of Regeneron, Lilly COVID-19 Antibodies


The U.S. government has paused the distribution of COVID-19 antibody treatments from Regeneron Pharmaceuticals (REGN.O) and Eli Lilly (LLY.N), saying the therapies were unlikely to be effective against the Omicron coronavirus variant.

The variant has become the dominant strain in the United States with lightning speed, resurrecting restrictions and stretching the country’s testing infrastructure.

Read More at Reuters

Be the first to comment!

The comment must be no longer than 400 characters 0/400